SHL.DE

49.35

+1.59%↑

ARGX

501

+4.59%↑

FRE

42.71

+0.54%↑

ONC.US

228

+2.7%↑

PHIA

21.56

+0.19%↑

SHL.DE

49.35

+1.59%↑

ARGX

501

+4.59%↑

FRE

42.71

+0.54%↑

ONC.US

228

+2.7%↑

PHIA

21.56

+0.19%↑

SHL.DE

49.35

+1.59%↑

ARGX

501

+4.59%↑

FRE

42.71

+0.54%↑

ONC.US

228

+2.7%↑

PHIA

21.56

+0.19%↑

SHL.DE

49.35

+1.59%↑

ARGX

501

+4.59%↑

FRE

42.71

+0.54%↑

ONC.US

228

+2.7%↑

PHIA

21.56

+0.19%↑

SHL.DE

49.35

+1.59%↑

ARGX

501

+4.59%↑

FRE

42.71

+0.54%↑

ONC.US

228

+2.7%↑

PHIA

21.56

+0.19%↑

Search

Sanofi SA

Abierto

SectorSanidad

91.86 2.86

Resumen

Variación precio

24h

Actual

Mínimo

89.37

Máximo

92.06

Métricas clave

By Trading Economics

Ingresos

1.4B

1.9B

Ventas

3B

11B

P/B

Media del Sector

18.265

56.602

BPA

1.79

Rentabilidad por dividendo

4.22

Margen de beneficios

17.65

Empleados

82,878

EBITDA

2.2B

2.8B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+30.33% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

4.22%

2.45%

Próximas Ganancias

31 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-19B

111B

Apertura anterior

89

Cierre anterior

91.86

Noticias sobre sentimiento de mercado

By Acuity

43%

57%

150 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Sanofi SA Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 may 2025, 11:29 UTC

Adquisiciones, fusiones, absorciones

Santander to Sell Poland Assets to Austria's Erste Group for $7.9 Billion -- 2nd Update

5 may 2025, 09:09 UTC

Adquisiciones, fusiones, absorciones

Santander to Sell Poland Assets to Austria's Erste Group for $7.9 Billion -- Update

5 may 2025, 07:25 UTC

Adquisiciones, fusiones, absorciones

Erste Group to Buy Santander Assets in Poland for $7.91 Billion

15 may 2025, 11:04 UTC

Charlas de Mercado
Ganancias

Spanish, Italian Banks Have Less Upside After Strong Run -- Market Talk

13 may 2025, 12:53 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Natwest's Reported Santander UK Interest Seems Surprising -- Market Talk

13 may 2025, 10:23 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Santander's Geographic Refocusing Can Lift Earning Estimates -- Market Talk

13 may 2025, 08:58 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Any Sale of Santander UK Would Need Strong Justification -- Market Talk

12 may 2025, 12:07 UTC

Charlas de Mercado

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

8 may 2025, 17:55 UTC

Ganancias

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

8 may 2025, 15:12 UTC

Ganancias

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

6 may 2025, 06:16 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Santander's Polish Business Disposal Is Attractive -- Market Talk

6 may 2025, 06:13 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Erste's Cash Deal for Santander Bank Polksa Seen as Positive -- Market Talk

5 may 2025, 14:11 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Erste Group Adds Exposure to Fast-Growing Polish Market, But Could Face Risk -- Market Talk

5 may 2025, 11:30 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Sale of Polish Business Strengthens Santander's Capital Position -- Market Talk

5 may 2025, 06:48 UTC

Adquisiciones, fusiones, absorciones

Santander Intends to Take Full Ownership of Santander Consumer Bank Polska

5 may 2025, 06:48 UTC

Adquisiciones, fusiones, absorciones

Santander Will Own 13% of Santander Polska Following Transaction

5 may 2025, 06:47 UTC

Adquisiciones, fusiones, absorciones

Santander, Erste Enter Cooperation in Corporate & Investment Banking, Payments

5 may 2025, 06:46 UTC

Adquisiciones, fusiones, absorciones

Santander Expects EUR2B Net Capital Gain From Deal

5 may 2025, 06:46 UTC

Adquisiciones, fusiones, absorciones

Erste Group Says Profitability Is Set to Improve Significantly After Deal

5 may 2025, 06:45 UTC

Adquisiciones, fusiones, absorciones

Erste Group Targets Return to Current Dividend Payout Range of 40-50% From 2026

5 may 2025, 06:45 UTC

Adquisiciones, fusiones, absorciones

Erste Group to Reduce 2025 Dividend Payout to Maximum of 10% of Net Profit

5 may 2025, 06:45 UTC

Adquisiciones, fusiones, absorciones

Erste Group: Dividend for 2024 Remains Unchanged at EUR3 a Share

5 may 2025, 06:44 UTC

Adquisiciones, fusiones, absorciones

Erste Group to Temporarily Reduce Dividend Payout

5 may 2025, 06:43 UTC

Adquisiciones, fusiones, absorciones

Erste Group to Cancel Planned EUR700M Buyback

5 may 2025, 06:42 UTC

Adquisiciones, fusiones, absorciones

Erste Group Will Fund the Acquisition Exclusively From Internal Resources

5 may 2025, 06:40 UTC

Adquisiciones, fusiones, absorciones

Santander Says It Plans to Distribute EUR3.2B Through Buybacks

5 may 2025, 06:39 UTC

Adquisiciones, fusiones, absorciones

Erste Group to Buy 49% of Santander Polska's for PLN584 a Share

5 may 2025, 06:38 UTC

Adquisiciones, fusiones, absorciones

Erste Group to Buy 49% Stake in Poland Unit of Banco Santander

5 may 2025, 06:37 UTC

Adquisiciones, fusiones, absorciones

Erste Group to Become No. 3 Bank in Poland Through Deal

5 may 2025, 06:36 UTC

Adquisiciones, fusiones, absorciones

Erste Group Also Acquires 50% in Asset Management Firm Santander TFI for EUR200M

Comparación entre iguales

Cambio de precio

Sanofi SA previsión

Precio Objetivo

By TipRanks

30.33% repunte

Estimación a 12 Meses

Media 115.786 EUR  30.33%

Máximo 127 EUR

Mínimo 95 EUR

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

15 ratings

11

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

91.3 / 96.1Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

150 / 382 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.